Menu Search
Equities

NeutriSci International Inc

1N9:MUN

NeutriSci International Inc

Actions
  • Price (EUR)0.001
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-80.00%
  • Beta--
Data delayed at least 15 minutes, as of Apr 05 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NeutriSci International Inc. (NeutriSci) is a Canada-based company, which specializes in the production, and formulation of nutraceutical products within the business-to-business (B2B) industry. The Company is focused on the market development for its nutraceutical products. Its products utilize patented form of Pterostilbene called pTeroPure. pTeroPure Pterostilbene is a form of all-trans Pterostilbene that is found naturally in blueberries and is manufactured for NeutriSci by ChromaDex Corp. (ChromaDex) in the United States. NeutriSci’s neuenergy product is an energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash that is associated with energy products. It has developed proprietary IP and technology (NeutriSci IP) that creates an efficient method of bilingual absorption of nutraceuticals into the bloodstream. NeutriSci’s IP can be applied to many different categories in the beverage, food, and nutraceutical space.

  • Revenue in CAD (TTM)59.98k
  • Net income in CAD-552.46k
  • Incorporated2014
  • Employees--
  • Location
    NeutriSci International Inc1600 - 609 Granville StVANCOUVER V7Y 1C3CanadaCAN
  • Phone+1 (778) 331-8505
  • Fax+1 (778) 331-8505
  • Websitehttps://neutrisci.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.